Key points from article :
ARPA-H launched the Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program to bioprint organs on demand.
PRINT aims to eliminate the need for immunosuppressive drugs after transplants.
The program will use 3D bioprinting technology and regenerative medicine.
It will initially focus on kidneys, livers, and hearts.
Seeks proposals focusing on generating necessary cells, manufacturing them, and biofabrication.
“If successful, this technology would decrease donor list wait times, reduce the need and cost, and make organs and tissues more widely available,” said ARPA-H Director Renee Wegrzyn.
